Washington, 13 Dec (EFE).-Michael Kalos, one of the researchers who developed the treatment that is healing to the seven year old little Emma Whitehead of his leukemia, today told Efe that “is soon to talk about cure,” but these advancements are a promising step in the fight against cancer.

Kalos, Member of the research group of the University of Pennsylvania, confessed being afraid even to pronounce the word “cure”, but he stressed that the progress experienced by the girl who this week took the covers due to the success of this therapy are very “satisfactory”.

treatment developed with a neutralized variant of the AIDS virus has managed, in just a few months, that Emma is in a State of ’deep remission’.

“For months we have not found a single cancer cell in the body of Emma”, said Kalos.

without Die Wissenschaftler erklärt, “sie müssen jedoch jahrelang bis wir Ruhe atmen kann”.

Eltern von Whitehead, verzweifelt nach dem Versuch andere Behandlungen, da das Mädchen 5 Jahre alt war, wusste, dass dieses Verfahren, das noch in der Entwicklung ist, und beschlossen, seine Tochter ins Krankenhaus für Kinder in Philadelphia, wo er angewendet. war Sie

Whitehead erhielt die Behandlung, genannt die Vergangenheit T-Zell-Immuntherapie April, die gemischt, die einmal mit einer neutralisierte HIV-Variante besteht in der Trennung von weißen Blutkörperchen (oder T-Zellen) erkennen und angreifen leukämischen Zellen, als ein Fahrzeug für die Antikörper.

bereits veränderte T-Zellen im Körper des Mädchens wieder eingeführt wurden und reduziert unterhalb der Erkennung, ein Prozess, der, obwohl es Tod verursachen könnte ihn um Vergebung. zu erreichen erlaubt hat, Leukämie

< p”>” Emma had no other option. had tried everything with it. the majority of children who suffer from this type of leukemia are able to cure in 80% of cases, but Emma was part of that 20% that do not react to any treatment “, said Kalos.

“leukemia is a cancer that is very easy to treat with this method, we are now investigating if we can apply it to other types of more complex cancers,”added.

Whitehead is one of 10 patients undergoing immunotherapy of T-cell leukemia from the University of Pennsylvania, and in the case of two of them, in very advanced age, already they have passed up to two years without cells cancerous.

pharmaceutical Novartis has bought the license for this technology and is developing the treatment to be marketed, rather than for the researchers of the University of Pennsylvania”Es ist eine große Chance “durch die große Erfahrung des Unternehmens in die medizinische Entwicklung gegen den Krebs. EFE